The SIX1-EYA transcriptional complex as a therapeutic target in cancer
- PMID: 25555392
- PMCID: PMC4336540
- DOI: 10.1517/14728222.2014.978860
The SIX1-EYA transcriptional complex as a therapeutic target in cancer
Abstract
Introduction: The SIX homeodomain proteins and the eyes absent (EYA) family of co-activators form a bipartite transcription factor complex that promotes the proliferation and survival of progenitor cells during organogenesis and is down-regulated in most adult tissues. Abnormal over-expression of SIX1 and EYA in adult tissue is associated with the initiation and progression of diverse tumor types. Importantly, SIX1 and EYA are often co-overexpressed in tumors, and the SIX1-EYA2 interaction has been shown to be critical for metastasis in a breast cancer model. The EYA proteins also contain protein tyrosine phosphatase activity, which plays an important role in breast cancer growth and metastasis as well as directing cells to the repair pathway upon DNA damage.
Areas covered: This review provides a summary of the SIX1/EYA complex as it relates to development and disease and the current efforts to therapeutically target this complex.
Expert opinion: Recently, there have been an increasing number of studies suggesting that targeting the SIX1/EYA transcriptional complex will potently inhibit tumor progression. Although current attempts to develop inhibitors targeting this complex are still in the early stages, continued efforts toward developing better compounds may ultimately result in effective anti-cancer therapies.
Keywords: inhibition of transcriptional complexes; metastasis; phosphatase; protein–protein interaction; six1/eyes absent complex; transcription factor.
Figures
Similar articles
-
Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties.Oncogene. 2012 Feb 2;31(5):552-62. doi: 10.1038/onc.2011.259. Epub 2011 Jun 27. Oncogene. 2012. PMID: 21706047 Free PMC article.
-
Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis.Cancer Res. 2020 Jun 15;80(12):2689-2702. doi: 10.1158/0008-5472.CAN-20-0435. Epub 2020 Apr 27. Cancer Res. 2020. PMID: 32341035 Free PMC article.
-
Regulation of cancer stem cell properties by SIX1, a member of the PAX-SIX-EYA-DACH network.Adv Cancer Res. 2019;141:1-42. doi: 10.1016/bs.acr.2018.12.001. Epub 2019 Jan 16. Adv Cancer Res. 2019. PMID: 30691681 Review.
-
Structure-function analyses of the human SIX1-EYA2 complex reveal insights into metastasis and BOR syndrome.Nat Struct Mol Biol. 2013 Apr;20(4):447-53. doi: 10.1038/nsmb.2505. Epub 2013 Feb 24. Nat Struct Mol Biol. 2013. PMID: 23435380 Free PMC article.
-
The EYA-SO/SIX complex in development and disease.Pediatr Nephrol. 2013 Jun;28(6):843-54. doi: 10.1007/s00467-012-2246-1. Epub 2012 Jul 19. Pediatr Nephrol. 2013. PMID: 22806561 Free PMC article. Review.
Cited by
-
Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery.Int J Mol Sci. 2020 Jul 24;21(15):5262. doi: 10.3390/ijms21155262. Int J Mol Sci. 2020. PMID: 32722222 Free PMC article. Review.
-
In Vitro Phosphatase Assays for the Eya2 Tyrosine Phosphatase.Methods Mol Biol. 2024;2743:285-300. doi: 10.1007/978-1-0716-3569-8_18. Methods Mol Biol. 2024. PMID: 38147222 Free PMC article.
-
Mammary gland stem cells and their application in breast cancer.Oncotarget. 2017 Feb 7;8(6):10675-10691. doi: 10.18632/oncotarget.12893. Oncotarget. 2017. PMID: 27793013 Free PMC article. Review.
-
SIX1 Predicts Poor Prognosis and Facilitates the Progression of Non-small Lung Cancer via Activating the Notch Signaling Pathway.J Cancer. 2022 Jan 1;13(2):527-540. doi: 10.7150/jca.61385. eCollection 2022. J Cancer. 2022. PMID: 35069900 Free PMC article.
-
The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth.Mol Cancer Ther. 2018 Aug;17(8):1659-1669. doi: 10.1158/1535-7163.MCT-18-0057. Epub 2018 May 25. Mol Cancer Ther. 2018. PMID: 29802120 Free PMC article.
References
-
- Ford HL, Kabingu EN, Bump EA, et al. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proc Natl Acad Sci U S A. 1998;95(21):12608–13. This is the first study to demonstrate overexpression of SIX1 in any tumor type, and to implicate it in cell cycle control in cancer. - PMC - PubMed
-
- Li X, Oghi KA, Zhang J, et al. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature. 2003;426(6964):247–54. One of the first studies to demonstrate that the Eya transcriptional cofactor contains intrinsic phosphatase activity, and that this may be critical for Six1-mediated transcription. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R41 CA180347/CA/NCI NIH HHS/United States
- 2T32082086-11A1/PHS HHS/United States
- R01CA095277/CA/NCI NIH HHS/United States
- R03 DA033174/DA/NIDA NIH HHS/United States
- R03DA030559/DA/NIDA NIH HHS/United States
- T32 CA082086/CA/NCI NIH HHS/United States
- R01 CA095277/CA/NCI NIH HHS/United States
- T32 CA174648/CA/NCI NIH HHS/United States
- R03DA033174/DA/NIDA NIH HHS/United States
- R01CA157790/CA/NCI NIH HHS/United States
- T32 GM008730/GM/NIGMS NIH HHS/United States
- R01 CA157790/CA/NCI NIH HHS/United States
- R03 DA030559/DA/NIDA NIH HHS/United States
- R41CA180347/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources